Santhera Pharmaceuticals Holding AG (SANN SW) stock market data APIs
CHF14.1314
0.19(1.3%)
as of April 17, 2025
Santhera Pharmaceuticals Holding AG Financial Data Overview
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Prev. Close
14.1314
Open
14.3252
High
14.3252
Low
13.9247
52 wk Range
7.21-17.76
Market Cap
179 M
P/E Ratio
2.4696
Shares Outstanding
12 595 K
Revenue
114 M
Beta
-0.251
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Santhera Pharmaceuticals Holding AG data using free add-ons & libraries
Get Santhera Pharmaceuticals Holding AG Fundamental Data
Santhera Pharmaceuticals Holding AG Fundamental data includes:
- Net Revenue: 114 M
- EBITDA: 57 274 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-23
- EPS/Forecast: NaN
Get Santhera Pharmaceuticals Holding AG End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Santhera Pharmaceuticals Holding AG News
New
Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy
Ad hoc announcement pursuant to Art. 53 LR Food and Drug Administration (FDA) approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in children and adults aged 2 year...
Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy
Ad hoc announcement pursuant to Art. 53 LR Committee for Medicinal Products for Human Use (CHMP) issues positive opinion for AGAMREE® (vamorolone) for the treatment Duchenne muscular dystrophy (DMD)...
Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Revenue from contracts with custom...
Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group
Ad hoc announcement pursuant to Art. 53 LR Chiesi Group acquires entire idebenone business including Raxone inLeber's hereditary optic neuropathy (LHON)Chiesi Group assumes French reimbursement liabi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
